[Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration]. 1988

M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
1st Dept. of Surgery, School of Medicine Nagasaki University.

The concentration of Tegafur, 5-FU and Uracil in tumor and normal tissue were measured in 47 colorectal cancer patients who had been administered UFT (400/mg) for seven days before operation. The concentration of Tegafur, 5-FU and Uracil in tumor was higher than in normal tissue (p less than 0.01), and the concentration of 5-FU was correlative to the concentration of Tegafur and Uracil in both tissues. The Dukes group and histological type were not related to the concentration of Tegafur, 5-FU and Uracil in either tissue. The uptake of each drug was good and high in tumor tissue.

UI MeSH Term Description Entries
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal

Related Publications

M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
October 2003, International journal of oncology,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
October 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
March 1997, Nihon Geka Gakkai zasshi,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
April 2012, Oncology letters,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
March 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
October 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
August 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
February 2014, The American journal of managed care,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
February 2024, Anticancer research,
M Tomita, and T Shimoyama, and T Hirano, and T Nakagoe, and T Shimizu, and H Kusano, and Y Fukuda, and K Eida, and T Ishii, and Y Kotake
January 2020, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,
Copied contents to your clipboard!